SCHEMBL24711194

SCHEMBL24711194

COC(=O)COc1cccc(NC(=O)c2ccc(NC(=O)c3ccco3)cc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 13/20 0.71
▸ MEN1 O00255 11/20 0.71
▸ MAPT P10636 7/20 0.71
▸ ALDH1A1 P00352 7/20 0.71
▸ GAA P10253 2/20 0.71
▸ HTT P42858 1/20 0.71
▸ SMN1; SMN2 Q16637 4/20 0.69
▸ TSHR P16473 4/20 0.69
▸ LMNA P02545 3/20 0.69
▸ MAPK1 P28482 2/20 0.69
▸ HPGD P15428 1/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ CYP3A4 P08684 1/20 0.69
▸ CYP2C9 P11712 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ TP53 P04637 1/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ NPSR1 Q6W5P4 2/20 0.67
▸ KDM4E B2RXH2 1/20 0.65
▸ NPC1 O15118 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534117 0.83 KMT2A (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL2527962 0.82 MAPT (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL2535208 0.81 MAPT (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL2533817 0.81 MAPT (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL10069472 0.79 KMT2A (0.83) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL24711259 0.79 SMN1; SMN2 (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL6632076 0.79 NPC1 (1.00) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL14006936 0.78 NPC1 (0.70) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL29106507 0.77 MEN1 (0.71) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL7162285 0.77 NPC1 (0.83) KMT2AMEN1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 KMT2A 3862/4885MEN1 4664/4885MAPT 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback